within Pharmacolibrary.Drugs.ATC.V;

model V03AB37
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.7833333333333333,
    adminDuration  = 600,
    adminMass      = 5.0,
    adminCount     = 1,
    Vd             = 0.0089,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran and is used as a reversal agent for the anticoagulant effects of dabigatran. It is approved for use in adult patients who require rapid reversal of dabigatran's anticoagulation due to emergency surgery, urgent procedures, or life-threatening or uncontrolled bleeding.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult volunteers after single 5 g intravenous dose.</p><h4>References</h4><ol><li><p>Wang, Z, et al., &amp; Cui, Y (2020). Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study. <i>Advances in therapy</i> 37(9) 3916–3928. DOI:<a href=&quot;https://doi.org/10.1007/s12325-020-01439-2&quot;>10.1007/s12325-020-01439-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32691242/&quot;>https://pubmed.ncbi.nlm.nih.gov/32691242</a></p></li><li><p>Glund, S, et al., &amp; Reilly, P (2015). A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. <i>Thrombosis and haemostasis</i> 113(5) 943–951. DOI:<a href=&quot;https://doi.org/10.1160/TH14-12-1080&quot;>10.1160/TH14-12-1080</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25789661/&quot;>https://pubmed.ncbi.nlm.nih.gov/25789661</a></p></li><li><p>Hu, TY, et al., &amp; Asirvatham, SJ (2016). Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. <i>Vascular health and risk management</i> 12 35–44. DOI:<a href=&quot;https://doi.org/10.2147/VHRM.S89130&quot;>10.2147/VHRM.S89130</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26937198/&quot;>https://pubmed.ncbi.nlm.nih.gov/26937198</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V03AB37;
